Literature DB >> 32349179

Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis.

Vincenzo Ronca1,2,3,4, Clara Mancuso1,4, Chiara Milani1,4, Marco Carbone1,4, Ye Htun Oo2,3, Pietro Invernizzi1,4.   

Abstract

Primary biliary cholangitis (PBC) is a cholestatic liver disease characterized by the destruction of the small and medium bile ducts. Its pathogenesis is still unknown. Despite the genome wide association study findings, the therapies targeting the cytokines pathway, tested so far, have failed. The concept of the biliary epithelium as a key player of the PBC pathogenesis has emerged over the last few years. It is now well accepted that the biliary epithelial cells (BECs) actively participate to the genesis of the damage. The chronic stimulation of BECs via microbes and bile changes the cell phenotype toward an active state, which, across the production of proinflammatory mediators, can recruit, retain, and activate immune cells. The consequent immune system activation can in turn damage BECs. Thus, the crosstalk between both innate and adaptive immune cells and the biliary epithelium creates a paracrine loop responsible for the disease progression. In this review, we summarize the evidence provided in literature about the role of BECs and the immune system in the pathogenesis of PBC. We also dissect the relationship between the immune system and the BECs, focusing on the unanswered questions and the future potential directions of the translational research and the cellular therapy in this area. ©2020 Society for Leukocyte Biology.

Entities:  

Keywords:  TLR; autoimmunity; biliary epithelial cells; primary biliary cholangitis

Mesh:

Year:  2020        PMID: 32349179     DOI: 10.1002/JLB.5MR0320-200R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  8 in total

Review 1.  Interplay between Mast Cells and Regulatory T Cells in Immune-Mediated Cholangiopathies.

Authors:  Natalia M Krajewska; Rémi Fiancette; Ye H Oo
Journal:  Int J Mol Sci       Date:  2022-05-24       Impact factor: 6.208

Review 2.  The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations.

Authors:  Lauren V Terry; Ye Htun Oo
Journal:  Front Immunol       Date:  2020-09-23       Impact factor: 7.561

Review 3.  The Nuclear Receptor PXR in Chronic Liver Disease.

Authors:  Katia Sayaf; Ilaria Zanotto; Francesco Paolo Russo; Daniela Gabbia; Sara De Martin
Journal:  Cells       Date:  2021-12-27       Impact factor: 6.600

Review 4.  Recognizing Dysfunctional Innate and Adaptive Immune Responses Contributing to Liver Damage in Patients With Cirrhosis.

Authors:  Ruchika Goel; Chundamannil Eapen Eapen
Journal:  J Clin Exp Hepatol       Date:  2021-10-14

Review 5.  Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease.

Authors:  N Richardson; G E Wootton; A G Bozward; Y H Oo
Journal:  Semin Immunopathol       Date:  2022-05-31       Impact factor: 11.759

Review 6.  New insights on the role of human leukocyte antigen complex in primary biliary cholangitis.

Authors:  Giacomo Mulinacci; Andrea Palermo; Alessio Gerussi; Rosanna Asselta; Merrill Eric Gershwin; Pietro Invernizzi
Journal:  Front Immunol       Date:  2022-08-31       Impact factor: 8.786

Review 7.  Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis.

Authors:  Samantha Sarcognato; Diana Sacchi; Federica Grillo; Nora Cazzagon; Luca Fabris; Massimiliano Cadamuro; Ivana Cataldo; Claudia Covelli; Alessandra Mangia; Maria Guido
Journal:  Pathologica       Date:  2021-06

8.  Single cell sequencing analysis identifies genetics-modulated ORMDL3+ cholangiocytes having higher metabolic effects on primary biliary cholangitis.

Authors:  Bingyu Xiang; Chunyu Deng; Fei Qiu; Jingjing Li; Shanshan Li; Huifang Zhang; Xiuli Lin; Yukuan Huang; Yijun Zhou; Jianzhong Su; Mingqin Lu; Yunlong Ma
Journal:  J Nanobiotechnology       Date:  2021-12-06       Impact factor: 10.435

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.